focus -WSS

focus

author：knowledge 2025-09-30 22:04:14 - browse：94

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

hotspot

WSS

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Change Healthcare outage fallout shows need for new oversight

Cybersecurity threat forces Lurie Children's to take systems offline

Boston's new lab space is opening empty

Do digital therapeutics have a future in medicine?

John Green on his newest strategy for fighting tuberculosis

knowledge

focus

entertainment

New air purifier tech could be key to improving indoor air quality

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Drug repurposing or repositioning? The language matters

Novo Nordisk to expand supply of Wegovy for U.S. patients

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

23andMe had bad news about my health. I wish a person had delivered it

FDA advisers back CAR

DIEP, the 'gold standard' of breast reconstruction, is under threat

WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

A $475,000 price tag for a new cancer drug: crazy or meh?

FDA advisers back CAR

Novo Nordisk to expand supply of Wegovy for U.S. patients

Time to name cancers by genetics, not organ of origin, expert says

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

hotspot

knowledge

hotspot

hotspot